Potential diagnostic markers for disseminated intravascular coagulation of sepsis.

[1]  Yun-Xia Chen,et al.  Predictive value of the complement system for sepsis-induced disseminated intravascular coagulation in septic patients in emergency department. , 2015, Journal of critical care.

[2]  M. Kroll,et al.  THROMBOSIS AND HEMOSTASIS von Willebrand factor is a cofactor in complement regulation , 2015 .

[3]  D. Saitoh,et al.  Efficacy of antithrombin in preclinical and clinical applications for sepsis-associated disseminated intravascular coagulation , 2014, Journal of Intensive Care.

[4]  D. Saitoh,et al.  Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey , 2014, Critical Care.

[5]  M. Borggrefe,et al.  Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment , 2014, Critical Care.

[6]  P. Libby,et al.  Neutrophil extracellular traps form predominantly during the organizing stage of human venous thromboembolism development , 2014, Journal of thrombosis and haemostasis : JTH.

[7]  D. D. de Lange,et al.  Active von Willebrand factor predicts 28-day mortality in patients with systemic inflammatory response syndrome. , 2014, Blood.

[8]  山川 一馬,et al.  Clinical evaluation of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation , 2014 .

[9]  Volker Huck,et al.  The various states of von Willebrand factor and their function in physiology and pathophysiology , 2014, Thrombosis and Haemostasis.

[10]  Ji-Eun Kim,et al.  Changes in Plasma Levels of Natural Anticoagulants in Disseminated Intravascular Coagulation: High Prognostic Value of Antithrombin and Protein C in Patients with Underlying Sepsis or Severe Infection , 2014, Annals of laboratory medicine.

[11]  N. Juffermans,et al.  Utility of thromboelastography and/or thromboelastometry in adults with sepsis: a systematic review , 2014, Critical Care.

[12]  R. Montgomery,et al.  Evaluation of von Willebrand Factor and von Willebrand Factor Propeptide in Models of Vascular Endothelial Cell Activation, Perturbation, and/or Injury , 2014, Toxicologic pathology.

[13]  H. Ishikura,et al.  New diagnostic strategy for sepsis-induced disseminated intravascular coagulation: a prospective single-center observational study , 2014, Critical Care.

[14]  T. Ohmori,et al.  Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study , 2014, Critical Care.

[15]  H. Ni,et al.  Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis , 2013, Thrombosis and Haemostasis.

[16]  A. Kristensen,et al.  Disseminated intravascular coagulation in a novel porcine model of severe Staphylococcus aureus sepsis fulfills human clinical criteria. , 2013, Journal of comparative pathology.

[17]  Takahiro Miyauchi,et al.  Recombinant Thrombomodulin Protects Mice against Histone-Induced Lethal Thromboembolism , 2013, PloS one.

[18]  M. Hayakawa,et al.  Normal prothrombinase activity, increased systemic thrombin activity, and lower antithrombin levels in patients with disseminated intravascular coagulation at an early phase of trauma: comparison with acute coagulopathy of trauma-shock. , 2013, Surgery.

[19]  A. Perner,et al.  Consecutive thrombelastography clot strength profiles in patients with severe sepsis and their association with 28-day mortality: a prospective study. , 2013, Journal of critical care.

[20]  J. Thachil,et al.  Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines , 2013, Journal of thrombosis and haemostasis : JTH.

[21]  T. Shimazu,et al.  Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis , 2013, Intensive Care Medicine.

[22]  N. Zhang,et al.  Circulating histones are mediators of trauma-associated lung injury. , 2013, American journal of respiratory and critical care medicine.

[23]  B. Engelmann,et al.  Thrombosis as an intravascular effector of innate immunity , 2012, Nature Reviews Immunology.

[24]  A. Mehrabi,et al.  Viscoelastic and aggregometric point‐of‐care testing in patients with septic shock – cross‐links between inflammation and haemostasis , 2012, Acta anaesthesiologica Scandinavica.

[25]  T. Iba,et al.  Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a prospective multicenter survey. , 2012, Thrombosis research.

[26]  D. Cook,et al.  Prognostic utility and characterization of cell-free DNA in patients with severe sepsis , 2012, Critical Care.

[27]  T. Nobori,et al.  Plasma ADAMTS13, von Willebrand factor (VWF) and VWF propeptide profiles in patients with DIC and related diseases. , 2012, Thrombosis research.

[28]  C. Esmon,et al.  Extracellular histones increase plasma thrombin generation by impairing thrombomodulin‐dependent protein C activation , 2011, Journal of thrombosis and haemostasis : JTH.

[29]  I. Maruyama,et al.  Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation , 2011, Journal of thrombosis and haemostasis : JTH.

[30]  K. Tracey,et al.  HMGB1 is a therapeutic target for sterile inflammation and infection. , 2011, Annual review of immunology.

[31]  D. Villers,et al.  Early rise in circulating endothelial protein C receptor correlates with poor outcome in severe sepsis , 2011, Intensive Care Medicine.

[32]  E. Conway.  Thrombomodulin and its role in inflammation , 2011, Seminars in Immunopathology.

[33]  M. Levi,et al.  DIC: which laboratory tests are most useful. , 2011, Blood reviews.

[34]  J. Hartwig,et al.  Extracellular DNA traps promote thrombosis , 2010, Proceedings of the National Academy of Sciences.

[35]  K. Preissner,et al.  Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases , 2010, Nature Medicine.

[36]  R. Saxena,et al.  A novel thromboelastographic score to identify overt disseminated intravascular coagulation resulting in a hypocoagulable state. , 2010, American journal of clinical pathology.

[37]  V. Pettilä,et al.  Thromboelastometry in patients with severe sepsis and disseminated intravascular coagulation , 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[38]  Ji-Eun Kim,et al.  Correlation between plasma activity of ADAMTS-13 and coagulopathy, and prognosis in disseminated intravascular coagulation. , 2009, Thrombosis research.

[39]  J. Thachil,et al.  Guidelines for the diagnosis and management of disseminated intravascular coagulation , 2009, British journal of haematology.

[40]  M. Bauer,et al.  Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure , 2009, Thrombosis and Haemostasis.

[41]  T. Nishimura,et al.  Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). , 2008, Advances in experimental medicine and biology.

[42]  B. Lämmle,et al.  ADAMTS‐13, von Willebrand factor and related parameters in severe sepsis and septic shock , 2007, Journal of thrombosis and haemostasis : JTH.

[43]  S. Kushimoto,et al.  Predicting the severity of systemic inflammatory response syndrome (SIRS)-associated coagulopathy with hemostatic molecular markers and vascular endothelial injury markers. , 2007, The Journal of trauma.

[44]  L. Trinquart,et al.  Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure* , 2007, Critical care medicine.

[45]  K. Boudjeltia,et al.  Diagnosis and prognosis of overt disseminated intravascular coagulation in a general hospital—Meaning of the ISTH score system, fibrin monomers, and lipoprotein–C‐reactive protein complex formation , 2006, American journal of hematology.

[46]  N. Aoki,et al.  Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial , 2007, Journal of thrombosis and haemostasis : JTH.

[47]  S. Yamada,et al.  High‐mobility group box 1 protein promotes development of microvascular thrombosis in rats , 2007, Journal of thrombosis and haemostasis : JTH.

[48]  C. Ball,et al.  Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. , 2007, Haematologica.

[49]  S. Opal,et al.  Coagulation abnormalities in critically ill patients , 2006, Critical care.

[50]  K. Boudjeltia,et al.  Diagnosis and prognosis of overt disseminated intravascular coagulation in a general hospital—Meaning of the ISTH score system, fibrin monomers, and lipoprotein–C‐reactive protein complex formation , 2006, American journal of hematology.

[51]  B. Jilma,et al.  Validation of rotation thrombelastography in a model of systemic activation of fibrinolysis and coagulation in humans , 2006, Journal of thrombosis and haemostasis : JTH.

[52]  T. Ohmori,et al.  Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. , 2006, Blood.

[53]  Y. Abe,et al.  Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation , 2005, Thrombosis and Haemostasis.

[54]  J. Dong.  Cleavage of ultra‐large von Willebrand factor by ADAMTS‐13 under flow conditions , 2005, Journal of thrombosis and haemostasis : JTH.

[55]  K. Larsson,et al.  Soluble thrombomodulin activity and soluble thrombomodulin antigen in plasma , 2005, Journal of thrombosis and haemostasis : JTH.

[56]  Kevin J. Tracey,et al.  High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal , 2005, Nature Reviews Immunology.

[57]  B. Jilma,et al.  Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation , 2005, Thrombosis and Haemostasis.

[58]  T. Iba,et al.  ASSOCIATION BETWEEN THE SEVERITY OF SEPSIS AND THE CHANGES IN HEMOSTATIC MOLECULAR MARKERS AND VASCULAR ENDOTHELIAL DAMAGE MARKERS , 2005, Shock.

[59]  E. de Jonge,et al.  Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation* , 2004, Critical care medicine.

[60]  S. Opal,et al.  Coagulation in sepsis , 2004, Intensive Care Medicine.

[61]  D. Nelson,et al.  Severe protein C deficiency predicts early death in severe sepsis , 2004, Critical care medicine.

[62]  Alain Cariou,et al.  Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569] , 2004, Critical care.

[63]  B. Lämmle,et al.  Elevated nucleosome levels in systemic inflammation and sepsis* , 2003, Critical care medicine.

[64]  Ray C. Paton,et al.  Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca(++)-dependent complex of C-reactive protein with very-low-density lipoprotein and is a novel marker of impending disseminated intravascular coagulation. , 2002, Blood.

[65]  V. Pettilä,et al.  Predictive value of antithrombin III and serum C-reactive protein concentration in critically ill patients with suspected sepsis , 2002, Critical care medicine.

[66]  S. Uehara,et al.  Separation and characterization of the molecular species of thrombomodulin in the plasma of diabetic patients. , 2001, Thrombosis research.

[67]  F B Taylor,et al.  Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation , 2001, Thrombosis and Haemostasis.

[68]  M. Yanagisawa,et al.  Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. , 2001, The Journal of clinical investigation.

[69]  T. Iba,et al.  The role of the endothelium in changes in procoagulant activity in sepsis. , 1998, Journal of the American College of Surgeons.

[70]  G. Broze,et al.  Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. , 1997, Blood.

[71]  T. Tanaka,et al.  The role of neutrophil elastase in human pulmonary artery endothelial cell injury. , 1997, International archives of allergy and immunology.

[72]  U. Raeth,et al.  Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: in vivo and in vitro studies. , 1996, Immunology.

[73]  C. Chopin,et al.  Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. , 1992, Chest.

[74]  Tatsuya Hayashi,et al.  Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation , 1992, American journal of hematology.

[75]  S. Rapaport,et al.  Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction. , 1991, Blood.

[76]  P. Sandset,et al.  Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[77]  R. Seitz,et al.  The disturbance of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution * , 1989, European journal of haematology.

[78]  J. Kilpatrick,et al.  Heparin promotes the inactivation of antithrombin by neutrophil elastase. , 1987, Science.

[79]  T. Barbui,et al.  Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia , 1984 .

[80]  T. Barbui,et al.  Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia. , 1984, Blood.

[81]  M. Génestal,et al.  Factor II Related Antigen and Antithrombin III Levels as Indicators of Liver Failure in Consumption Coagulopathy , 1982, Thrombosis and Haemostasis.

[82]  S. Lewis.  British Committee for Standards in Haematology , 1969 .